Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Allergy News
US FDA Gives Green Light to Phase II/III Trial of NexEos Bio’s Vernal Keratoconjunctivitis Candidate
NexEos Bio reported on Feb. 19 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II/III trial of NTX-1024, a topical can...
Clinical Trial Updates for Ophthalmic Candidates , January 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
US FDA Approves ANI Pharmaceuticals’ Cortrophin Gel in Prefilled Syringe
ANI Pharmaceuticals announced March 3 that the US FDA had approved a prefilled syringe of its purified Cortrophin gel. Among its many indications, the treatment targets acute and chronic inflammato...
Nicox Reports First Sale of Zerviate in China by Partner Ocumension
France’s Nicox reported Dec. 4 that its partner Ocumension Therapeutics had made the first commercial sale of Zerviate (cetirizine ophthalmic solution) 0.24% in China. Zerviate is indicated for ocu...
Harrow Lowers Price of Drugs through GoodRx Partnership, Price Cuts
Harrow, of Nashville, Tennessee reported Nov. 13 that it had entered into a partnership with GoodRx to provide patients for whom insurance is not a viable option a cash-pay alternative. Harrow prod...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.